# Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects

> **NCT05102552** · EARLY_PHASE1 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** SPN-817, Treatment B
- **DRUG:** SPN-817, Treatment C
- **DRUG:** BIS-001, Treatment A

## Key facts

- **NCT ID:** NCT05102552
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-19
- **Primary completion:** 2022-03-25
- **Final completion:** 2022-08-15
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05102552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05102552, "Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05102552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*